Innovent Biologics, a leading biopharmaceutical company, announced that it will present clinical data on its innovative bispecific antibodies and antibody-drug conjugates (ADCs) at the ASCO Annual Meeting 2025. The presentations will feature IBI363 for melanoma, colorectal cancer, and non-small cell lung cancer, alongside Phase 1b data for IBI343 in pancreatic cancer. Senior VP Dr. Hui Zhou emphasized the importance of these presentations in addressing significant clinical needs and bolstering Innovent's commitment to advancing effective cancer treatments through its robust pipeline and technology platforms.
"At the 2025 ASCO Annual Meeting, we are excited to present our first wave of innovative bispecific antibodies targeting melanoma, colorectal cancer, and non-small cell lung cancer."
"The maturing PoC data for our innovative candidates has strengthened our confidence in advancing them into pivotal-stage development to unlock their clinical value."
Collection
[
|
...
]